Hutchison China MediTech
Hong Kong, China

Hutchison China MediTech (Chi-Med), a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

Hutchison China MediTech (Chi-Med) continues to gather momentum as its pipeline gets closer to unlocking its potential. Increased visibility for the three lead assets with multiple catalysts in the next 6 to 18 months suggest significant upside potential. In China, Chi-Med is leveraging its established base to build a fully integrated oncology business, with its c 320-strong China Oncology commercial team set to take over Elunate marketing from October and execute its first unpartnered China launch in Q420 assuming surufatinib approval. A ninth drug candidate discovered in-house (HMPL-306) has entered the clinic in China, while five assets are in development for global markets. The first FDA submission (surufatinib) should start before year-end, with fruquintinib and savolitinib in or approaching global registration trials. Our updated valuation is £5.87/share or $38.17/ADS.

Market information



ESMO 2020: SANET-p delivers further positive suru data
Update | 22 Sep 2020
Innovative pipeline closer to realising its potential
Update | 10 Aug 2020
General Atlantic invests $100m at 10% premium
Lighthouse | 25 Jun 2020

Recent News

Surufatinib Phase III data in NETs at ESMO 2020 and Publication in The Lancet Oncology
20 Sep 2020
Acceptance of second China NDA for surufatinib in pNET
17 Sep 2020
Initiation of global fruquintinib FRESCO-2 Phase III in mCRC
04 Sep 2020
Initiation of HMPL-453 China Phase II in advanced intrahepatic cholangiocarcinoma
03 Sep 2020